183 related articles for article (PubMed ID: 7663532)
1. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
2. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population.
Jurima-Romet M; Goldstein JA; LeBelle M; Aubin RA; Foster BC; Walop W; Rode A
Pharmacogenetics; 1996 Aug; 6(4):329-39. PubMed ID: 8873219
[TBL] [Abstract][Full Text] [Related]
6. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose.
Feng HJ; Huang SL; Wang W; Zhou HH
Br J Clin Pharmacol; 1998 Jan; 45(1):27-9. PubMed ID: 9489590
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population.
Xie HG; Huang SL; Xu ZH; Xiao ZS; He N; Zhou HH
Pharmacogenetics; 1997 Apr; 7(2):115-9. PubMed ID: 9170148
[TBL] [Abstract][Full Text] [Related]
8. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
9. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
10. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
Tybring G; Bertilsson L
Pharmacogenetics; 1992 Oct; 2(5):241-3. PubMed ID: 1306124
[TBL] [Abstract][Full Text] [Related]
11. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study.
Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA
Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266
[TBL] [Abstract][Full Text] [Related]
12. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
14. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais SM; Wilkinson GR; Blaisdell J; Nakamura K; Meyer UA; Goldstein JA
J Biol Chem; 1994 Jun; 269(22):15419-22. PubMed ID: 8195181
[TBL] [Abstract][Full Text] [Related]
15. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
Takakubo F; Kuwano A; Kondo I
Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
[TBL] [Abstract][Full Text] [Related]
16. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
[TBL] [Abstract][Full Text] [Related]
17. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
19. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
Goldstein JA; Blaisdell J
Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779
[No Abstract] [Full Text] [Related]
20. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
Kubota T; Chiba K; Ishizaki T
Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]